Skip to main content
AVIR logo

AVIR · Atea Pharmaceuticals, Inc.

Track AVIR — free
$3.96 +0.03 (+0.76%) At close · Nov 20
Market Cap
$318.00M
Shares
80.30M
Volume · Nov 20 416.47K Avg daily vol (3M) 289.48K

Price & Indicators

 

Key stats

Close
$3.96
Fri 20 Nov
Open
$3.88
Fri 20 Nov
Average volume, 30 days
315K
shares a session
Short interest
3.0M
3.7% of shares · 9.6 days to cover
Day range
$3.80$4.09
Open $3.88 Close $3.96
52-week closing range
$2.97$6.15
Close $3.96 35.6% under the high
Short volume, last session
39%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Oct 2020 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 9
Earnings call
Phase 3 HCV trial met primary endpoint with comparable cure rates

Atea Pharmaceuticals said its Phase 3 HCV trial met the primary endpoint, delivering 94% SBR versus 95% for standard care with an eight-week regimen for non-cirrhotic patients. Global trial results are targeted for early 2027, with an NDA submission in mid-2027.

6 source passages
Atea Pharmaceuticals' third quarter, 2026 Financial Results and Business Update Conference Call. Let's now review the Phase 3 results on Slide 10. In the primary endpoint MITT population, Ben-Rusevir achieved a 94% SBR rate compared with 95% for soft bell at WIC24, encompassing SBR12, the accepted definition of cure for HCV. These results met the primary endpoint of statistical non-inferiority within the pre-specified 5% margin. Bemrusesvir delivered cure rates comparable to the standard of care while offering an eight-week regimen for non-sirotic patients, which represent the majority of the patients in North America, compared to 12 weeks of soft bell. We are on track to report top line results in early 2027 for Sea Forward. Which is our global trial that enroll patients in 17 countries. This result, together with CBR, are expected to support a new drug application submission targeted for mid-2027 with the U.S. FDA. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
BEM/RZR meets endpoints; funding seen into mid-2028

BEM/RZR met C-BEYOND’s primary and secondary endpoints, achieving 93.9% SVR versus 94.8% for SOF/VEL. C-FORWARD topline results are expected in the first quarter 2027, followed by a targeted FDA submission in the second quarter 2027; funding is expected into mid-2028.

Net loss $32.16M Diluted EPS -$0.40
Read from the MD&A section
6 source passages
In July 2026, we announced positive topline results from C-BEYOND with BEM/RZR demonstrating statistical non-inferiority compared to SOF/VEL in the modified intent-to-treat (“mITT”) population thereby achieving the trial’s primary endpoint. In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL at Week 24 from the start of treatment, encompassing SVR at 12 weeks post-treatment (the generally accepted definition of cure for HCV) in both arms. Statistical non-inferiority was also met in secondary endpoints, including the per-protocol analysis. Currently, we anticipate to report the topline results from C-FORWARD in the first quarter of 2027. Pending successful results from C-FORWARD, we are targeting submission to the U.S. Food and Drug Administration (“FDA”) of a New Drug Application (“NDA”) for marketing approval in the second quarter of 2027. We believe that our available cash, including the $65.0 million that we have drawn under the Loan and Security Agreement, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2028. Open the document at this passage
Nov 9
Current report 8-K
BEM/RZR endpoints met; $200 million facility, cash runway into mid-2028

Atea Pharmaceuticals reported that BEM/RZR met primary and secondary endpoints in Phase 3 C-BEYOND, secured a Hercules Capital credit facility for up to $200 million, and had $191.2 million in cash and investments, with current resources expected to fund operations into mid-2028.

Financial results
4 source passages
During the third quarter, Atea announced positive topline results from C-BEYOND, the Company’s Phase 3 trial in North America, with the regimen of bemnifosbuvir/ruzasvir (BEM/RZR) demonstrating statistical non-inferiority to Epclusa® (sofosbuvir/velpatasvir; SOF/VEL) in patients with hepatitis C virus (HCV), meeting the primary and secondary endpoints. On November 9, 2026, Atea announced that it entered into a credit facility agreement with Hercules Capital, Inc. for up to $200 million. Cash and Investments: $191.2 million at September 30, 2026 compared to $301.8 million at December 31, 2025. Based on its current operating plan together with its current cash, cash equivalents and investments, the Company anticipates that these current resources will fund planned operations into mid-2028. Open the document at this passage
Nov 9
Current report 8-K Events of Nov 6
Hercules-backed $200.0 million facility includes Phase 3 condition

Atea Pharmaceuticals entered a Hercules Capital senior secured term loan facility of up to $200.0 million on November 6, 2026, with $65.0 million drawn and $35.0 million conditioned on successful Phase 3 completion for BEM/RZR.

Entered into a material agreement, New debt or off-balance-sheet obligation Read from the first part of this long document
3 source passages
On November 6, 2026 (the “Closing Date”), Atea Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), as agent, and the lenders party thereto, providing for term loans in an aggregate principal amount of up to $200.0 million, subject to the terms and conditions set forth therein. The Agreement provides for senior secured term loans which mature on November 1, 2031 (the “Maturity Date”), for up to $200.0 million and consists of the following tranches (collectively, the “Term Loans”): (1) a Tranche 1 Term Loan of $65.0 million drawn on the Closing Date, (2) a Tranche 2 Term Loan of up to $35.0 million, (3) a Tranche 3 Term Loan up to the difference between $35.0 million and the amounts funded under Tranche 4, (4) a Tranche 4 Term Loan up to the difference between $70.0 million and the amounts funded under Tranche 3, and (5) a Tranche 5 Term Loan of up to $30.0 million. The Tranche 2 Term Loan is available subject to certain conditions, including the successful completion, prior to a specified date in the second half of 2027, of the Company’s ongoing Phase 3 clinical trial, which is evaluating the fixed-dose combination of bemnifosbuvir and ruzasvir (“BEM/RZR”). Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$155.40M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$97.92M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.5%
Year over year · more shares
Price change (1Y)
+32.0%
Trailing year
Short interest
3.7%
Latest settlement · 9.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. C-BEYOND met its primary endpoint, C-FORWARD is fully enrolled, AT-587 advanced, and current resources are expected to fund planned operations into mid-2028. Cash and investments declined, interest income fell, and the HCV elimination bill is expected not to proceed without being reintroduced.

Bullish
  • + BEM/RZR met the C-BEYOND primary endpoint with a 93.91% SVR rate versus 94.75% for SOF/VEL.
  • + C-FORWARD is fully enrolled with more than 880 patients across 17 countries, with topline results expected in early 2027.
  • + Atea drew down $65 million from its credit facility and expects current resources to fund operations into mid-2028.
  • + AT-587 completed the single-ascending-dose portion and is progressing through multiple-ascending-dose testing.
  • + BEM/RZR co-administration with methadone or Suboxone was generally well tolerated and showed no drug-drug interactions.
  • + The credit facility is non-dilutive and strengthens Atea’s financial position.
Bearish
  • − Cash and investments declined to $191.2 million at September 30, 2026 from $301.8 million at December 31, 2025.
  • − Interest income and other, net declined by $1.8 million year over year because of lower investment balances.
  • − Management expects the pending HCV elimination bill not to proceed and would need to be reintroduced.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −15%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 31%
mid-range
Momentum
relative strength
Neutral
1-month return −2%
trailing
6-month return −7%
trailing
YTD return +11%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +17 funds added
Insider flow Distributing
Net -$319.8K over 90 days · 100% sells
Short interest Falling
3.75% of shares out · ▼ -2.0% MoM · 9.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
130 holders — near 3-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Strong
Revenue growth +622%
Y/Y
EPS growth +3%
Y/Y
Free cash flow $-134.0M
Buyback $11.1M
remaining
Balance sheet $95.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −36%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 9, 2026
Additional funding · subject to the achievement of specified milestones and other ter up to $135M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
31% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +17 funds added
Insider flow Distributing
Net -$319.8K over 90 days · 100% sells
Short interest Falling
3.75% of shares out · ▼ -2.0% MoM · 9.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
130 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 31% Range high $6
vs 200-day avg -20% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
HCV external costs 17.4M the three months ended September 30, 2026 filing —
Hercules credit facility drawdown at closing $65M November 6, 2026 —
HEV external costs 2.72M the three months ended September 30, 2026 filing —
Internal research and development costs 6.98M the three months ended September 30, 2026 filing —
SVR rate (BEM/RZR, mITT at Week 24) 93.91% C-BEYOND mITT analysis at Week 24 —
SVR rate (SOF/VEL, mITT at Week 24) 94.75% C-BEYOND mITT analysis at Week 24 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AVIR
Atea Pharmaceuticals, Inc.
this stock
$318.00M +10.9% +622.5% — 3.7%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
130
% held
73.5%
Net QoQ
-426.3K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
152
View
Short & Settlement
Short Interest Falling
Shares short
3.0M
Days to cover
9.6d
Change
-62.2K sh
View
Short Volume
Short vol %
39%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
566
Value
$2.4K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
28.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$319.8K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$351.4M
Net income (FY)
$-158.3M
EPS diluted
$-1.94
View
Buybacks
Authorized
$25.0M
Remaining
$11.1M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
14

Atea Pharmaceuticals reported that BEM/RZR met primary and secondary endpoints in Phase 3 C-BEYOND, secured a Hercules Capital credit facility for up to $200 million, and had $191.2 million in cash and investments, with current resources expected to fund operations into mid-2028.

View
Proposed Sales
Value
$35.3K
Shares
8.8K
Filed
Nov 19, 2026
View
Exempt Offerings
Offering
$215.0M
Filed
May 29, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Atea Pharmaceuticals Reports Thir…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
AVIR -7.9% -2.0% -7.3% -3.7% +10.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +0.7% +7.3% +1.9% +5.1% +9.8%

Capital returns

Buyback program · as of Jun 30, 2025
Authorized
$25.00M
Spent (derived)
$13.91M
Remaining
$11.09M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1593899 CUSIP 04683R106 13F (30d) 135 filings 118 filers Visit website Investor relations